JPWO2020028461A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020028461A5 JPWO2020028461A5 JP2021505202A JP2021505202A JPWO2020028461A5 JP WO2020028461 A5 JPWO2020028461 A5 JP WO2020028461A5 JP 2021505202 A JP2021505202 A JP 2021505202A JP 2021505202 A JP2021505202 A JP 2021505202A JP WO2020028461 A5 JPWO2020028461 A5 JP WO2020028461A5
- Authority
- JP
- Japan
- Prior art keywords
- halo
- alkoxy
- alkyl
- metastatic
- thioalkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000005843 halogen group Chemical group 0.000 claims 33
- 229910052739 hydrogen Inorganic materials 0.000 claims 17
- 239000001257 hydrogen Substances 0.000 claims 17
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 14
- -1 nitro, hydroxy Chemical group 0.000 claims 13
- 125000005309 thioalkoxy group Chemical group 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 12
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 11
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 11
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims 10
- 150000002431 hydrogen Chemical class 0.000 claims 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 10
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 10
- 230000001394 metastastic effect Effects 0.000 claims 7
- 206010061289 metastatic neoplasm Diseases 0.000 claims 7
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 6
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 claims 6
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims 4
- 125000006698 (C1-C3) dialkylamino group Chemical group 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 208000037819 metastatic cancer Diseases 0.000 claims 3
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010055113 Breast cancer metastatic Diseases 0.000 claims 1
- 206010055114 Colon cancer metastatic Diseases 0.000 claims 1
- 206010050017 Lung cancer metastatic Diseases 0.000 claims 1
- 206010027452 Metastases to bone Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000010658 metastatic prostate carcinoma Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862712434P | 2018-07-31 | 2018-07-31 | |
| US62/712,434 | 2018-07-31 | ||
| PCT/US2019/044278 WO2020028461A1 (en) | 2018-07-31 | 2019-07-31 | Tetrahydroquinolino derivatives for the treatment of metastatic and chemoresistant cancers |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021532158A JP2021532158A (ja) | 2021-11-25 |
| JP2021532158A5 JP2021532158A5 (https=) | 2022-08-04 |
| JPWO2020028461A5 true JPWO2020028461A5 (https=) | 2022-08-04 |
| JP7613743B2 JP7613743B2 (ja) | 2025-01-15 |
Family
ID=67734803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021505202A Active JP7613743B2 (ja) | 2018-07-31 | 2019-07-31 | 転移性癌および化学療法抵抗性癌の治療のためのテトラヒドロキノリノ誘導体 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12162855B2 (https=) |
| EP (1) | EP3830079A1 (https=) |
| JP (1) | JP7613743B2 (https=) |
| CN (1) | CN112638881B (https=) |
| AU (1) | AU2019315444B2 (https=) |
| CA (1) | CA3107120A1 (https=) |
| IL (1) | IL280395B2 (https=) |
| WO (1) | WO2020028461A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112638881B (zh) | 2018-07-31 | 2025-01-07 | 普林斯顿大学托管委员会 | 用于治疗转移性和化疗耐受性癌症的四氢喹啉衍生物 |
| CA3168533A1 (en) * | 2020-01-24 | 2021-07-29 | The Trustees Of Princeton University | Heterocyclic compounds and uses thereof |
| GB202019475D0 (en) | 2020-12-10 | 2021-01-27 | Cancer Research Tech Ltd | Therapeutic compounds and their use |
| KR102925139B1 (ko) | 2021-04-22 | 2026-02-10 | 카요테라 인코포레이티드 | 헤테로시클릭 화합물 및 이의 용도 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60126270A (ja) * | 1983-12-14 | 1985-07-05 | Otsuka Pharmaceut Co Ltd | カルボスチリル誘導体 |
| JPS61145162A (ja) * | 1984-12-19 | 1986-07-02 | Otsuka Pharmaceut Co Ltd | カルボスチリル誘導体 |
| DE3701277A1 (de) | 1987-01-17 | 1988-07-28 | Boehringer Mannheim Gmbh | Neue tricyclische benzimidazole, verfahren zu ihrer herstellung und verwendung als arzneimittel |
| JPH01319453A (ja) * | 1988-06-22 | 1989-12-25 | Wakamoto Pharmaceut Co Ltd | 新規ベンゾキノン誘導体 |
| MXPA05012086A (es) | 2003-05-12 | 2006-02-22 | Pfizer Prod Inc | Inhibidores de benzamida del receptor p2x7. |
| CN102225926A (zh) * | 2003-11-07 | 2011-10-26 | 诺华疫苗和诊断公司 | 具有改进药物特性的喹啉酮类化合物的药学上可接受的盐 |
| US7875624B2 (en) * | 2004-02-20 | 2011-01-25 | Novartis Vaccines And Diagnostics, Inc. | Modulating and measuring cellular adhesion |
| JP2006349902A (ja) * | 2005-06-15 | 2006-12-28 | Fujifilm Holdings Corp | 黒白熱現像感光材料 |
| EP2021502A4 (en) * | 2006-05-09 | 2010-08-25 | Mas Metabolic Analytical Servi | GENES AND ATYPICAL MARKERS IN TYPE 2 DIABETES AND OBESITY |
| US8541404B2 (en) | 2009-11-09 | 2013-09-24 | Elexopharm Gmbh | Inhibitors of the human aldosterone synthase CYP11B2 |
| WO2013027168A1 (en) | 2011-08-22 | 2013-02-28 | Pfizer Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
| KR102319882B1 (ko) * | 2014-02-19 | 2021-11-03 | 아비브 테라퓨틱스, 인크. | 암의 치료를 위한 폴리사이클릭 아미드와 결합하는 미토콘드리아 알데히드 탈수소효소 2 (aldh2) 및 그의 용도 |
| WO2015173169A1 (en) | 2014-05-12 | 2015-11-19 | Fondazione Istituto Italiano Di Tecnologia | Substituted benzoxazolone derivatives as acid ceramidase inhibitors, and their use as medicaments |
| RU2743074C2 (ru) | 2014-08-01 | 2021-02-15 | Нуэволюшон А/С | Соединения, активные по отношению к бромодоменам |
| CN112638881B (zh) | 2018-07-31 | 2025-01-07 | 普林斯顿大学托管委员会 | 用于治疗转移性和化疗耐受性癌症的四氢喹啉衍生物 |
| CA3168533A1 (en) | 2020-01-24 | 2021-07-29 | The Trustees Of Princeton University | Heterocyclic compounds and uses thereof |
| GB202019475D0 (en) | 2020-12-10 | 2021-01-27 | Cancer Research Tech Ltd | Therapeutic compounds and their use |
| KR102925139B1 (ko) | 2021-04-22 | 2026-02-10 | 카요테라 인코포레이티드 | 헤테로시클릭 화합물 및 이의 용도 |
-
2019
- 2019-07-31 CN CN201980056669.3A patent/CN112638881B/zh active Active
- 2019-07-31 IL IL280395A patent/IL280395B2/en unknown
- 2019-07-31 EP EP19758540.9A patent/EP3830079A1/en active Pending
- 2019-07-31 JP JP2021505202A patent/JP7613743B2/ja active Active
- 2019-07-31 WO PCT/US2019/044278 patent/WO2020028461A1/en not_active Ceased
- 2019-07-31 CA CA3107120A patent/CA3107120A1/en active Pending
- 2019-07-31 AU AU2019315444A patent/AU2019315444B2/en active Active
-
2021
- 2021-01-29 US US17/162,827 patent/US12162855B2/en active Active
-
2024
- 2024-11-01 US US18/934,691 patent/US20250129046A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025163128A5 (https=) | ||
| RU97105381A (ru) | Соединения и способы для лечения рака | |
| WO2021068952A1 (zh) | 靶向醛酮还原酶1c3的苯并二氢吡喃类化合物 | |
| JP2007511504A5 (https=) | ||
| KR20110013411A (ko) | (ｆ-19)-표지된 ｌ-글루탐산 및 ｌ-글루타민 유도체 (ⅲ), 그의 용도 및 그의 수득 방법 | |
| JP2017534657A (ja) | 新型シチジン誘導体およびその適用 | |
| JP2021532158A5 (https=) | ||
| JP7732678B2 (ja) | リン酸塩誘導体およびその用途 | |
| JPWO2020028461A5 (https=) | ||
| CN109516926B (zh) | 一种荜茇明碱衍生物制备及用途 | |
| JP2022502378A5 (https=) | ||
| CN112175014B (zh) | 一种一氧化氮供体型四价铂衍生物、制备方法及其医药用途 | |
| JP2004528293A5 (https=) | ||
| US20060089332A1 (en) | Phosphate-bearing prodrugs of sulfonyl hydrazines as hypoxia-selective antineoplastic agents | |
| US11370766B2 (en) | Sulfonyl amidine as indoleamine-2,3-dioxygenase inhibitor, and preparation method therefor and use thereof | |
| CN112266396B (zh) | 一种基于生物正交化学的整合型前药、制备方法及其医药用途 | |
| CN112624949B (zh) | 手性二芳基-β-内酰胺类化合物及其制备方法和制药用途 | |
| US5599825A (en) | Water-soluble methine compound and pharmaceutical composition for treatment of cancer comprising the same | |
| JP5249753B2 (ja) | ジカルボン酸誘導体、転移阻害剤および抗腫瘍調製物の化学療法活性を増大する薬剤、細胞増殖抑制剤の効果を増大する方法および転移プロセスの阻害のための方法 | |
| RU2025115630A (ru) | Производные тиадиазолила в качестве ингибиторов днк-полимеразы тета и их применение | |
| JPWO2020049166A5 (https=) | ||
| JPH10506878A (ja) | 水溶性メチン化合物及び該化合物を含有する癌治療用医薬組成物 | |
| JP7853957B2 (ja) | ピラゾールボロン酸化合物、それを含有する医薬組成物、及びそれらの使用 | |
| CN114380728B (zh) | 新型二芳基-β-内酰胺类有机硒化合物及其制备方法和在制药中的用途 | |
| EP4491620A1 (en) | Crystal form of isochroman compound |